Search

Your search keyword '"Urukami T"' showing total 3 results
Start Over Author "Urukami T"
3 results on '"Urukami T"'

1. The genetic and regulatory architecture of ERBB3-type 1 diabetes susceptibility locus

Author

Kaur, S., Mirza, A. H., Brorsson, C. A., Fløyel, T., Størling, J., Mortensen, H. B., Pociot, F., Aanstoot, H.-J., De Beaufort, Carine, Cameron, F., Castano, L., Dorchy, H., Fisher, L., Kaprio, E., Lange, K., Neu, A., Njolstad, P. R., Phillip, M., Urukami, T., Barrett, T., Chiarelli, F., Danne, T., Hoey, H., Kocova, M., Mortensen, B., Schoenle, J., Swift, G. F., Vanelli, M., Åman, J., and Robert, J.J.

Subjects
Beta cell, endocrine system, Type 1 diabetes, endocrine system diseases, B lymphocyte, Multidisciplinaire, généralités & autres [D99] [Sciences de la santé humaine], Apoptosis, CTCF, LncRNAs, ERBB3, ERBB3 gene, Article, Multidisciplinary, general & others [D99] [Human health sciences]
Abstract

The study aimed to explore the role of ERBB3 in type 1 diabetes (T1D). We examined whether genetic variation of ERBB3 (rs2292239) affects residual β-cell function in T1D cases. Furthermore, we examined the expression of ERBB3 in human islets, the effect of ERBB3 knockdown on apoptosis in insulin-producing INS-1E cells and the genetic and regulatory architecture of the ERBB3 locus to provide insights to how rs2292239 may confer disease susceptibility. rs2292239 strongly correlated with residual β-cell function and metabolic control in children with T1D. ERBB3 locus associated lncRNA (NONHSAG011351) was found to be expressed in human islets. ERBB3 was expressed and down-regulated by pro-inflammatory cytokines in human islets and INS-1E cells; knockdown of ERBB3 in INS-1E cells decreased basal and cytokine-induced apoptosis. Our data suggests an important functional role of ERBB3 and its potential regulators in the β-cells and may constitute novel targets to prevent β-cell destruction in T1D. © 2015 Elsevier Ireland Ltd.

Published
2016

2. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009

Author

De Beaufort, Carine, Lange, K., Swift, P.G., Aman, J., Cameron, F., Castano, L., Dorchy, H., Fisher, L.K., Hoey, H., Kaprio, E., Kocova, M., Neu, A., Njolstad, P.R., Phillip, M., Schoenle, E., Robert, J.J., Urukami, T., Vanelli, M., Danne, T., Barrett, T., Chiarelli, F., Aanstoot, H.J., Mortensen, H.B., De Beaufort, Carine, Lange, K., Swift, P.G., Aman, J., Cameron, F., Castano, L., Dorchy, H., Fisher, L.K., Hoey, H., Kaprio, E., Kocova, M., Neu, A., Njolstad, P.R., Phillip, M., Schoenle, E., Robert, J.J., Urukami, T., Vanelli, M., Danne, T., Barrett, T., Chiarelli, F., Aanstoot, H.J., and Mortensen, H.B.

Abstract

Objective: To investigate whether center differences in glycemic control are present in prepubertal children <11 yr with type 1 diabetes mellitus. Research Design and Methods: This cross-sectional study involved 18 pediatric centers worldwide. All children, <11 y with a diabetes duration ≥12 months were invited to participate. Case Record Forms included information on clinical characteristics, insulin regimens, diabetic ketoacidosis (DKA), severe hypoglycemia, language difficulties, and comorbidities. Hemoglobin A1c (HbA1c) was measured centrally by liquid chromatography (DCCT aligned, range: 4.4-6.3%; IFFC: 25-45 mmol/mol). Results: A total of 1133 children participated (mean age: 8.0 ± 2.1 y; females: 47.5%, mean diabetes duration: 3.8 ± 2.1 y). HbA1c (overall mean: 8.0 ± 1.0%; range: 7.3-8.9%) and severe hypoglycemia frequency (mean 21.7 events per 100 patient-years), but not DKA, differed significantly between centers (p < 0.001 resp. p = 0.179). Language difficulties showed a negative relationship with HbA1c (8.3 ± 1.2% vs. 8.0 ± 1.0%; p = 0.036). Frequency of blood glucose monitoring demonstrated a significant but weak association with HbA1c (r = -0.17; p < 0.0001). Although significant different HbA1c levels were obtained with diverse insulin regimens (range: 7.3-8.5%; p < 0.001), center differences remained after adjusting for insulin regimen (p < 0.001). Differences between insulin regimens were no longer significant after adjusting for center effect (p = 0.199). Conclusions: Center differences in metabolic outcomes are present in children <11 yr, irrespective of diabetes duration, age, or gender. The incidence of severe hypoglycemia is lower than in adolescents despite achieving better glycemic control. Insulin regimens show a significant relationship with HbA1c but do not explain center differences. Each center's effectiveness in using specific treatment strategies remains the key factor for outcome.

Published
2012

3. Metabolic outcomes in young children with type 1 diabetes differ between treatment centers: the Hvidoere Study in Young Children 2009.

Author

de Beaufort CE, Lange K, Swift PG, Aman J, Cameron F, Castano L, Dorchy H, Fisher LK, Hoey H, Kaprio E, Kocova M, Neu A, Njolstad PR, Phillip M, Schoenle E, Robert JJ, Urukami T, Vanelli M, Danne T, Barrett T, Chiarelli F, Aanstoot HJ, and Mortensen HB

Subjects
Child, Cohort Studies, Cross-Sectional Studies, Diabetes Mellitus, Type 1 blood, Diabetes Mellitus, Type 1 complications, Diabetes Mellitus, Type 1 physiopathology, Diabetic Ketoacidosis chemically induced, Diabetic Ketoacidosis epidemiology, Diabetic Ketoacidosis physiopathology, Female, Glycated Hemoglobin analysis, Humans, Hyperglycemia epidemiology, Hypoglycemia epidemiology, Hypoglycemic Agents adverse effects, Incidence, Insulin adverse effects, Male, Severity of Illness Index, Time Factors, Diabetes Mellitus, Type 1 drug therapy, Diabetic Ketoacidosis prevention & control, Hyperglycemia prevention & control, Hypoglycemia prevention & control, Hypoglycemic Agents therapeutic use, Insulin therapeutic use
Abstract

Objective: To investigate whether center differences in glycemic control are present in prepubertal children <11 yr with type 1 diabetes mellitus., Research Design and Methods: This cross-sectional study involved 18 pediatric centers worldwide. All children, <11 y with a diabetes duration ≥12 months were invited to participate. Case Record Forms included information on clinical characteristics, insulin regimens, diabetic ketoacidosis (DKA), severe hypoglycemia, language difficulties, and comorbidities. Hemoglobin A1c (HbA1c) was measured centrally by liquid chromatography (DCCT aligned, range: 4.4-6.3%; IFFC: 25-45 mmol/mol)., Results: A total of 1133 children participated (mean age: 8.0 ± 2.1 y; females: 47.5%, mean diabetes duration: 3.8 ± 2.1 y). HbA1c (overall mean: 8.0 ± 1.0%; range: 7.3-8.9%) and severe hypoglycemia frequency (mean 21.7 events per 100 patient-years), but not DKA, differed significantly between centers (p < 0.001 resp. p = 0.179). Language difficulties showed a negative relationship with HbA1c (8.3 ± 1.2% vs. 8.0 ± 1.0%; p = 0.036). Frequency of blood glucose monitoring demonstrated a significant but weak association with HbA1c (r = -0.17; p < 0.0001). Although significant different HbA1c levels were obtained with diverse insulin regimens (range: 7.3-8.5%; p < 0.001), center differences remained after adjusting for insulin regimen (p < 0.001). Differences between insulin regimens were no longer significant after adjusting for center effect (p = 0.199)., Conclusions: Center differences in metabolic outcomes are present in children <11 yr, irrespective of diabetes duration, age, or gender. The incidence of severe hypoglycemia is lower than in adolescents despite achieving better glycemic control. Insulin regimens show a significant relationship with HbA1c but do not explain center differences. Each center's effectiveness in using specific treatment strategies remains the key factor for outcome., (© 2012 John Wiley & Sons A/S.)

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results